30 closest matches · ranked by relevance
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
Colon Cancer · Pancreatic Cancer · Cholangiocarcinoma
Primary: Number of Participants With Disease Recurrence At 1 Year — 2; 0 Participants
Cancer
Primary: Number of Participants and Type of Reported Adverse Events — 25; 22; 22; 6 Participants
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
Advanced Solid Malignancies
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Progressive Metastatic Malignancies
Primary: The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies — 0; 2; 4 Events
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Oncology · Solid Tumors
Primary: Part A: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events…
Advanced Malignant Neoplasm · Metastatic Malignant Neoplasm · Unresectable Malignant Neoplasm
Primary: Number of Participants With Dose-Limiting Toxicity — 0; 1; 0; 0 Participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Advanced Melanoma · Non-small Cell Lung Cancer · Renal Cell Carcinoma
Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants
Carcinoma, Non-Small-Cell Lung · Colorectal Cancer · Malignant Melanoma
Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…
Melanoma
Primary: Objective Response Rate — 25 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants